Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study

Diabetes Care
David M KendallRalph A DeFronzo

Abstract

We sought to evaluate the effects of muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor (PPAR) activator within the new glitazar class, on hyperglycemia and lipid abnormalities. A double-blind, randomized, controlled trial was performed in 1,159 patients with type 2 diabetes inadequately controlled with metformin. Patients received once-daily doses of either 5 mg muraglitazar or 30 mg pioglitazone for a total of 24 weeks in addition to open-label metformin. Patients were continued in a double-blind fashion for an additional 26 weeks. Analyses were conducted at week 24 for HbA1c (A1C) and at week 12 for lipid parameters. Mean A1C at baseline was 8.12 and 8.13% in muraglitazar and pioglitazone groups, respectively. At week 24, muraglitazar reduced mean A1C to 6.98% (-1.14% from baseline), and pioglitazone reduced mean A1C to 7.28% (-0.85% from baseline; P < 0.0001, muraglitazar vs. pioglitazone). At week 12, muraglitazar and pioglitazone reduced mean plasma triglyceride (-28 vs. -14%), apolipoprotein B (-12 vs. -6%), and non-HDL cholesterol (-6 vs. -1%) and increased HDL cholesterol (19 vs. 14%), respectively (P < 0.0001 vs. pioglitazone for all comparisons). At week 24, weight gain (1.4 and 0.6 kg, res...Continue Reading

Citations

Dec 16, 2006·Current Atherosclerosis Reports·Jennifer G Robinson
Sep 1, 2007·Hepatology International·David van der Poorten, Jacob George
Feb 18, 2010·Current Opinion in Endocrinology, Diabetes, and Obesity·Aaron M Cypess, C Ronald Kahn
Feb 22, 2012·International Journal of Clinical Practice·A S WierzbickiA Viljoen
Feb 22, 2008·PPAR Research·Anna C Calkin, Merlin C Thomas
Feb 22, 2008·PPAR Research·Jennifer G Robinson
Jul 22, 2009·Cardiovascular Diabetology·Enrique Z Fisman, Alexander Tenenbaum
Oct 4, 2011·The Open Medicinal Chemistry Journal·Ernest AdeghateHuba Kalasz
Dec 18, 2013·Middle East African Journal of Ophthalmology·Gopal Lingam, Tien Yin Wong
Jan 8, 2014·Current Atherosclerosis Reports·Parag GoyalWilliam B Borden
Nov 24, 2007·Pharmacogenomics·Sharon Cresci
Jan 13, 2009·Current Opinion in Lipidology·Karin A M Jandeleit-DahmMerlin Thomas
Oct 17, 2009·American Journal of Therapeutics·Zafar H Israili
Feb 19, 2008·Journal of Clinical Gastroenterology·Richard H Moseley
Sep 22, 2010·Expert Opinion on Therapeutic Targets·Marc van Bilsen, Frans A van Nieuwenhoven
Nov 27, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kjeld Hermansen, Lene S Mortensen
Sep 25, 2012·Heart Failure Clinics·Jeong-a KimMichael J Quon
Jul 25, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·F BiscettiA Flex
Apr 8, 2009·Bioorganic & Medicinal Chemistry Letters·Agnes BénardeauPeter Mohr
Apr 9, 2008·Gastroentérologie Clinique Et Biologique·S DharancyL Dubuquoy
Dec 7, 2007·Best Practice & Research. Clinical Endocrinology & Metabolism·Barbara Gross, Bart Staels
Oct 13, 2007·Diabetes Research and Clinical Practice·Matteo MonamiEdoardo Mannucci
Feb 20, 2007·The American Journal of Cardiology·Gabriel I Uwaifo, Robert E Ratner
Mar 28, 2009·ChemMedChem·Uwe GretherDaniel Schlatter
Oct 2, 2007·British Journal of Pharmacology·C E QuinnG E McVeigh
Dec 3, 2008·Diabetic Medicine : a Journal of the British Diabetic Association·C Lloret-LinaresS Czernichow
Oct 30, 2007·ChemMedChem·Oliver RauManfred Schubert-Zsilavecz
Aug 8, 2007·American Journal of Reproductive Immunology : AJRI·Bettina TothUdo Jeschke
Oct 7, 2010·Journal of Diabetes·Eric M ChangKelly L Close
Aug 14, 2010·Journal of Clinical Pharmacology·Sindhu AkkatiGirish Tungha
Jan 1, 2012·Scientifica·Giuseppe Danilo Norata
Feb 23, 2013·PPAR Research·Andreea CiudinRafael Simó
Dec 9, 2014·Diabetic Medicine : a Journal of the British Diabetic Association·D K ColettaR A DeFronzo
Mar 27, 2010·Journal of the American College of Cardiology·Pradeep NatarajanChristopher P Cannon
May 15, 2012·Bioorganic & Medicinal Chemistry Letters·Taejung KimJungyeob Ham

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.